- ALZFORUM | NETWORKING FOR A CURE
A large proteogenomic study identified 49 pQTLs, in either CSF or plasma, linked to cerebral small vessel disease Immune and ECM proteins predominated
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
- The Discovery and Development of Liraglutide and Semaglutide . . . - ALZFORUM
Knudsen LB, Lau J The Discovery and Development of Liraglutide and Semaglutide Front Endocrinol (Lausanne) 2019;10:155 Epub 2019 Apr 12 PubMed
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the . . .
Zhang L, Zhang L, Li L, Hölscher C Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease J Parkinsons Dis 2019;9 (1):157-171
- Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction . . .
Rubin R Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? JAMA 2024 May 14;331 (18):1519-1521 PubMed
- Exenatide - ALZFORUM
The short-acting form of exenatide is administered by twice-daily subcutaneous self-injection; a long-acting preparation is injected just once a week In mice, exenatide readily crossed the blood-brain barrier, while other GLP-1 mimetics liraglutide and semaglutide did not (Salameh et al , 2020)
- Empagliflozin - ALZFORUM
Empagliflozin belongs to the gliflozin class of glucose-lowering agents that includes dapagliflozin These drugs inhibit the sodium-glucose cotransporter-2 (SGLT2), which is responsible for 90 percent of glucose reabsorption into the kidney As a result, excess glucose is secreted via the urine, helping reduce blood glucose, alleviate glucose toxicity, improve insulin sensitivity, and promote
- Liraglutide - ALZFORUM
Background Liraglutide is an analog of glucagon-like peptide 1 GLP-1 is a hormone that is produced in the gut and activates receptors in the gut, liver, and pancreas to control blood-sugar levels and reduce insulin resistance Liraglutide and related GLP-1 mimetics cause body weight loss and reduce the risk of cardiovascular events, stroke, and dementia in people with diabetes
|